Amani Therapeutics Closes $25 Million Series A to Advance AM-01, a Potential Best-in-Class Therapy for Serious Neuropsychiatric Disorders [Yahoo! Finance]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
The company also announced the appointment of its executive leadership team and the in-licensing of worldwide rights from AstraZeneca to a Phase 3–ready novel chemical entity (NCE), which is a component of Amani's lead program, AM-01. Amani's mission is to develop highly efficacious, safer medicines for people living with serious neuropsychiatric disorders. About AM-01 AM-01 is a fixed-dose combination product that includes clozapine and a Phase 3–ready NCE with worldwide rights in-licensed from AstraZeneca. Amani believes AM-01 has the potential to deliver clozapine's unmatched efficacy for patients with schizophrenia while addressing clozapine's most significant safety liability—severe neutropenia—and the burdensome blood-monitoring that limit its use. Clozapine remains the only medication proven to meaningfully improve symptoms in treatment-resistant schizophrenia and to reduce suicide risk in patients with schizophrenia and schizoaffective disorder. Despite its clinical be
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill. [Yahoo! Finance]Yahoo! Finance
- Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend? [Yahoo! Finance]Yahoo! Finance
- OverT Bio Announces the Formation of the Clinical Advisory Board to Support the Clinical Development of OVT-101 in Ovarian Cancer and Other Solid Tumors [Yahoo! Finance]Yahoo! Finance
- 3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income [Yahoo! Finance]Yahoo! Finance
- Three New Studies Show Viz.ai's Cardio Suite Speeds Detection of Cardiac Disease and Improves Patient Follow-Up [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 2/6/26 - Beat
BMY
Sec Filings
- 3/12/26 - Form 4
- 3/12/26 - Form 4
- 3/12/26 - Form 4
- BMY's page on the SEC website